Fosun Pharmaceuticals (02196): Subsidiaries Pharmaceuticals, Fosun Pharmaceutical Industries and Pfizer jointly signed a “License Agreement”

Zhitongcaijing · 12/09/2025 11:49

Zhitong Finance App News, Fosun Pharmaceuticals (02196) issued an announcement. On December 9, 2025, the company's holding subsidiaries, Yakyu Pharmaceuticals, Fosun Pharmaceutical Industry, and Pfizer jointly signed a “License Agreement”. (This mainly includes) Pharmacogon-like Pharmaceuticals grants Pfizer exclusive development, use, production and commercialization rights for oral small molecule glucagon-like peptide-1 receptor (including YP05002) agonists (including YP05002) and products containing this active ingredient in the licensed region (that is, worldwide) and fields (treatment, diagnosis and prevention of all indications in humans and animals); just GLP-1R Under this license, Yaoyou Pharmaceutical will be entitled to receive (including) a non-refundable down payment of 150 million US dollars and development milestone payments of up to 350 million US dollars based on clinical and commercialization progress of the licensed product.

According to reports, YP05002 is an oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist independently developed by the Group and has independent intellectual property rights; it mainly promotes pancreatic insulin secretion and reduces glucagon secretion by activating human GLP-1R, inhibits gastric emptying and intestinal peristalsis in the gastrointestinal tract, and reduces energy intake by influencing central appetite to treat type 2 diabetes, obesity, and related diseases. YP05002 is intended for the treatment of diseases related to the metabolic field. Potential indications include, but are not limited to, long-term weight management, type 2 diabetes, and steatohepatitis associated with metabolic dysfunction (i.e. non-alcoholic steatohepatitis). As of December 9, 2025, YP05002 is in phase I clinical trials in Australia.

This license reflects the partner's recognition of the Group's innovative R&D capabilities. Through this license, it is conducive to speeding up clinical development and commercialization of licensed products on a global scale, and is expected to benefit more patients around the world.